Human Trials Begin for COVID-19 Plant-Based Technology VaccineJuly 22, 2020
The Quebec City-based company is able to develop a clinical-grade vaccine candidate in a matter of weeks using plant-based technology. They create their products with virus-like particles (VLP) instead of animal products or live viruses. The VLPs mimic the shape of the virus and allows the human body to recognize them, thus creating an immune response in a non-infectious way.
The Phase I Clinical Trials is a partially blinded study with 180 healthy participants. Three doses, 3.75, 7.5, and 15 micrograms, of the recombinant Corona Virus-Like Particle (CoVLP) vaccine candidate will be evaluated. The doses may be administered with the vaccine candidate alone, or with an adjuvant in a prime-boost regimen. An adjuvant is considered important during a pandemic because it boosts the immune response and reduces the amount of antigen required per dose. This allows the production of more vaccine doses thus maximizing the number of people that can be protected.
The Phase 2/3 Trial is also expected to initiate in October 2020.
Read Medicago's press release to learn more.
You might also like:
- Viable Vaccine Candidate for COVID-19 Developed Using Proprietary Plant-based Technology
- First Results from Human COVID-19 Immunology Study Identify Universally Effective Antibodies
- Pocket K No. 58: COVID-19 Treatment Efforts Using Plant Technologies
Biotech Updates is a weekly newsletter of ISAAA, a not-for-profit organization. It is distributed for free to over 22,000 subscribers worldwide to inform them about the key developments in biosciences, especially in biotechnology. Your support will help us in our mission to feed the world with knowledge. You can help by donating as little as $10.
See more articles:
News from Around the World
- GM Crops' Impact Creates a Halo Effect, Expert Explains
- ISAAA Launches Open-access Resources on Genome Editing
- Oat Genome Now on ARS Website
- Most Accurate Map of Pig Genome Gives Insights to Breeding Healthier Animals
- Researchers Develop Fine-tune Methods for Gene Silencing
- Scientists Use CRISPR-Cas9 for Single-nucleotide Editing in Rice
- TALENs Used to Edit Mitochondrial DNA
- Experts Review Methods Used to Minimize Off-Target Effects in Genome Editing
- Researchers Turn to CRISPR Genome Editing to Make Cyanide-Free Cassava
- Structural Analysis of COVID-19 Spike Protein Describes its Evolution
- Researchers Identify Possible Immune Targets in SARS-CoV-2 Genome
- Human Trials Begin for COVID-19 Plant-Based Technology Vaccine
Read the latest:
- Biotech Updates (November 29, 2023)
- Gene Editing Supplement (November 29, 2023)
- Gene Drive Supplement (February 22, 2023)
Subscribe to BU: